Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Profiling breast cancer with expression arrays has become common, and it has been suggested that the results from early studies will lead to understanding of the molecular differences between clinical cases and allow individualization of care. We critically review two main applications of expression profiling; studies unraveling novel breast cancer classifications and those that aim to identify novel markers for prediction of clinical outcome. Breast cancer may now be subclassified into luminal, basal, and HER2 subtypes with distinct differences in prognosis and response to therapy. However, profiling studies to identify predictive markers have suffered from methodologic problems that prevent general application of their results. Future work will need to reanalyze existing microarray data sets to identify more representative sets of candidate genes for use as prognostic signatures and will need to take into account the new knowledge of molecular subtypes of breast cancer when assessing predictive effects.

Original publication

DOI

10.1200/JCO.2005.03.3845

Type

Journal article

Journal

J Clin Oncol

Publication Date

10/10/2005

Volume

23

Pages

7350 - 7360

Keywords

Biomarkers, Tumor, Breast Neoplasms, Female, Forecasting, Gene Expression Profiling, Genetic Markers, Humans, Outcome Assessment (Health Care), Predictive Value of Tests